Frontiers in Pediatrics (Sep 2023)

The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)

  • Pablo Velasco,
  • Francisco Bautista,
  • Alba Rubio,
  • Yurena Aguilar,
  • Susana Rives,
  • Susana Rives,
  • Jose L. Dapena,
  • Jose L. Dapena,
  • Antonio Pérez,
  • Antonio Pérez,
  • Antonio Pérez,
  • Manuel Ramirez,
  • Cristina Saiz-Ladera,
  • Elisa Izquierdo,
  • Elisa Izquierdo,
  • Adela Escudero,
  • Adela Escudero,
  • Mireia Camós,
  • Mireia Camós,
  • Mireia Camós,
  • Nerea Vega-García,
  • Nerea Vega-García,
  • Margarita Ortega,
  • Margarita Ortega,
  • Gloria Hidalgo-Gómez,
  • Gloria Hidalgo-Gómez,
  • Carlos Palacio,
  • Carlos Palacio,
  • Pablo Menéndez,
  • Pablo Menéndez,
  • Pablo Menéndez,
  • Pablo Menéndez,
  • Clara Bueno,
  • Clara Bueno,
  • Clara Bueno,
  • Clara Bueno,
  • Joan Montero,
  • Joan Montero,
  • Paola A. Romecín,
  • Paola A. Romecín,
  • Santiago Zazo,
  • Federico Alvarez,
  • Juan Parras,
  • Carmen Ortega-Sabater,
  • Salvador Chulián,
  • Salvador Chulián,
  • María Rosa,
  • María Rosa,
  • Davide Cirillo,
  • Elena García,
  • Jorge García,
  • Albert Manzano-Muñoz,
  • Albert Manzano-Muñoz,
  • Alfredo Minguela,
  • Alfredo Minguela,
  • Jose L. Fuster,
  • Jose L. Fuster

DOI
https://doi.org/10.3389/fped.2023.1269560
Journal volume & issue
Vol. 11

Abstract

Read online

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with survival rates exceeding 85%. However, 15% of patients will relapse; consequently, their survival rates decrease to below 50%. Therefore, several research and innovation studies are focusing on pediatric relapsed or refractory ALL (R/R ALL). Driven by this context and following the European strategic plan to implement precision medicine equitably, the Relapsed ALL Network (ReALLNet) was launched under the umbrella of SEHOP in 2021, aiming to connect bedside patient care with expert groups in R/R ALL in an interdisciplinary and multicentric network. To achieve this objective, a board consisting of experts in diagnosis, management, preclinical research, and clinical trials has been established. The requirements of treatment centers have been evaluated, and the available oncogenomic and functional study resources have been assessed and organized. A shipping platform has been developed to process samples requiring study derivation, and an integrated diagnostic committee has been established to report results. These biological data, as well as patient outcomes, are collected in a national registry. Additionally, samples from all patients are stored in a biobank. This comprehensive repository of data and samples is expected to foster an environment where preclinical researchers and data scientists can seek to meet the complex needs of this challenging population. This proof of concept aims to demonstrate that a network-based organization, such as that embodied by ReALLNet, provides the ideal niche for the equitable and efficient implementation of “what's next” in the management of children with R/R ALL.

Keywords